Lisa Schmitz Mazur

Nov 18, 2024 | natlawreview.com | Lisa Schmitz Mazur

The US Drug Enforcement Administration (DEA) further extended flexibilities that allow providers to prescribe controlled substances via telemedicine without first performing an in-person visit. The flexibilities were initially provided during the COVID-19 public health emergency (PHE) and were scheduled to expire on December 31, 2024. This extension extends the flexibilities through December 31, 2025.

Oct 17, 2024 | natlawreview.com | Lisa Schmitz Mazur

Skip to main content October 17, 2024 Volume XIV, Number 291 Legal Analysis. Expertly Written. Quickly Found.

Oct 11, 2024 | natlawreview.com | Lisa Schmitz Mazur

A new rule posted on the Office of Management and Budget (OMB) registry suggests that the Drug Enforcement Administration (DEA) is planning an additional extension of COVID-19 flexibilities for telemedicine prescribing of controlled substances, beyond the current expiration date of December 31, 2024. The new rule is entitled “Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications” and is not yet available for public review.

Sep 11, 2024 | natlawreview.com | Lisa Schmitz Mazur

Skip to main content September 11, 2024 Volume XIV, Number 255 Legal Analysis. Expertly Written. Quickly Found.

Aug 22, 2024 | employeebenefitsblog.com | Lisa Schmitz Mazur |Patrick Zanayed |Nathan Gray |Travis Jackson

In California, pending Assembly Bill 3129 could severely limit the ability of digital health companies to grow and operate in the state by prohibiting arrangements between physician, psychiatric, and dental practices and any entity that furnishes business or management services to providers that accept investments from private equity groups and hedge funds.